This randomized clinical trial examines the association of prostate-specific membrane antigen positron emission tomography (PET)–guided intensification of salvage radiotherapy with failure-free survival among patients with prostate cancer after radical prostatectomy. This evidence concerns the gene FOLH1 and Familial prostate cancer.